Previously, we have demonstrated that another orphan NR TLX, which displays an upregulation expression in advanced prostate cancer cells, can perform an oncogenic function in prostate cancer, by suppressing cellular senescence via its differential co-regulation of CDKN1A and transactivation of the SIRT1 gene in a p53-independent manner [54]. This evidence concerns the gene TP53 and prostate carcinoma.